{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:55:19Z","timestamp":1759366519911,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.revmed.2022.07.013","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T22:51:29Z","timestamp":1659653489000},"page":"673-676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Int\u00e9r\u00eat du daratumumab dans l\u2019amylose AL r\u00e9fractaire chez une patiente de 96 ans"],"prefix":"10.1016","volume":"43","author":[{"given":"G.","family":"Vial","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lafargue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Merci\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Duffau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2022.07.013_bib0085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-021-00486-4","article-title":"Comprehensive review of AL amyloidosis: some practical recommendations","volume":"11","author":"Al Hamed","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.revmed.2022.07.013_bib0090","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2022.07.013_bib0095","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/13506129.2020.1765768","article-title":"Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed\/refractory AL amyloidosis","volume":"27","author":"Cohen","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.revmed.2022.07.013_bib0100","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A prospective phase 2\u00a0trial of daratumumab in patients with previously treated systemic light-chain amyloidosis","volume":"135","author":"Roussel","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2022.07.013_bib0105","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2\u00a0study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2022.07.013_bib0110","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.18632\/aging.101707","article-title":"How I treat elderly patients with plasma cell dyscrasias","volume":"10","author":"Gavriatopoulou","year":"2018","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.revmed.2022.07.013_bib0115","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejim.2018.05.004","article-title":"Management of the elderly patient with AL amyloidosis","volume":"58","author":"Nuvolone","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.revmed.2022.07.013_bib0120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajh.26399","article-title":"Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab","volume":"97","author":"Szalat","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2022.07.013_bib0125","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41375-019-0667-6","article-title":"IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features","volume":"34","author":"Sidana","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2022.07.013_bib0130","unstructured":"Traitement sp\u00e9cifique de l\u2019amylose AL n.d. http:\/\/www.unilim.fr\/cr-amylose-al\/medecins\/prise-en-charge\/traitement_amylose\/.(accessed June 25, 2022)."},{"key":"10.1016\/j.revmed.2022.07.013_bib0135","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2020008737","article-title":"How I treat AL amyloidosis","volume":"139","author":"Palladini","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2022.07.013_bib0140","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.humpath.2018.09.008","article-title":"IgM plasma cell myeloma in the era of novel therapy: a clinicopathological study of 17\u00a0cases","volume":"84","author":"Angelova","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.revmed.2022.07.013_bib0145","first-page":"5089","article-title":"Multicenter phase 2\u00a0study of daratumumab monotherapy in patients with previously treated Waldenstr\u00f6m macroglobulinemia","volume":"4","author":"Castillo","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.revmed.2022.07.013_bib0150","doi-asserted-by":"crossref","first-page":"1182384","DOI":"10.1155\/2022\/1182384","article-title":"Utility of Bruton's tyrosine kinase inhibitors in light chain amyloidosis caused by lymphoplasmacytic lymphoma (Waldenstr\u00f6m's macroglobulinemia)","volume":"2022","author":"Bou Zerdan","year":"2022","journal-title":"Adv Hematol"},{"key":"10.1016\/j.revmed.2022.07.013_bib0155","article-title":"COVID-19\u00a0vaccine responses in patients with plasma cell dyscrasias after complete vaccination","author":"Shah","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.revmed.2022.07.013_bib0080","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jama.2021.24931","article-title":"(Evusheld) for pre-exposure prophylaxis of COVID-19","volume":"327","author":"Tixagevimab and cilgavimab","year":"2022","journal-title":"JAMA"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866322005793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866322005793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:45:33Z","timestamp":1759337133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866322005793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0248866322005793"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2022.07.013","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Int\u00e9r\u00eat du daratumumab dans l\u2019amylose AL r\u00e9fractaire chez une patiente de 96ans","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2022.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}